**BACKGROUND**

**METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC) - UNMET MEDICAL NEED**

Outcomes in many solid tumors, mCRPC remains largely resistant to such therapies with single agent response rates around 6% (Keynote 199 ASCO-GU 2020). Further exploration has been focused on combination therapies.

**BxCL701 MECHANISM OF ACTION**

A critical role of the innate immune system is to alert the adaptive immune system of an invading pathogen. The Cytokine/Chemokine signaling leads to increase in immune cell infiltration, cells monocytes, NK and IL-1ß, bridging between innate and adaptive immunity.

**BxCL701 ACTIVITY IS MEDIATED BY DPP9 INHIBITION**

The key to inflammatory pathway activation is the activation of caspase 1 and the extracellular production of a host of cytokines and chemokines including IL-1ß, IL-18 and IL-8. The Cytokine/Chemokine signaling leads to increase in immune cell infiltration, cells monocytes, NK and IL-1ß, bridging between innate and adaptive immunity. Activation of caspase 1 by BxCL701 has been shown to be critical for the decrease in the levels of cytokines and chemokines, leading to an antitumor immune response.

**METHODS**

**ORAL DOSIMETRIC AND KEY OBJECTIVES**

**RESULTS**

**PRELIMINARY ACTIVITY OBSERVED IN ADENOCARCINOMA POPULATION**

**PHASE 2 SAFETY IN ADENOCARCINOMA POPULATION**

**CONCLUSION**

**SERUM PSA BEST OVERALL CHANGE**

**THANK YOU**

BioXcel would also like to thank the participating investigators and their staff for their support on this study and their willingness to contribute to the field of clinical research and patient care.